Materials and methods for nerve grafting comprising degrading chondroitin sulfate proteoglycan
CA 2886815 C · Owner: University Of Florida Research Foundation, Inc. · Inventors: Muir, David Fulton
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns methods of preparing nerve grafts by treatment with CSPG-degrading enzymes. Exemplary CSPG-degrading enzymes include chondroitinase e.g. chondroitinase ABC, chondroitinase A chondroitinase C and chondroitinase AC; a hyaluronidase; and a matrix metalloproteinase (MMP) e.g. MMP-2 and MMP-9. In one embodiment the nerve tissue is rendered acellular after treatment. The nerve tissue can be rendered acellular by freeze-killing. The present invention also concerns methods of culturing fresh nerve tissue for subsequent implantation as a nerve graft into a human or animal. The nerve tissue can be cultured under physiological conditions that permit the tissue to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 13, 2002 and granted April 3, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 13, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 13, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.